HER2-Positive Cancers
HER2-Positive Cancers are a group of cancers that have an overexpression of the HER2 protein, which can lead to aggressive tumor growth. These cancers often require targeted therapies that specifically address the HER2 protein.
HER2-Expressing Cancers: VIR-5818 and Pembrolizumab Study
We are testing a new treatment combining VIR-5818 with Pembrolizumab for patients with advanced or metastatic HER2-expressing cancers. This study aims to evaluate the safety and effects of this combination.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Institut De Cancerologie De L Ouest
Medical Oncology
Avignon, France
Oncopole Claudius Regaud
Medical Oncology
Portet-sur-Garonne, France
Institut Gustave Roussy
Département d'Innovation Thérapeutique et des Essais Précoces (DITEP)
Villejuif, France
Sponsor: Vir Biotechnology Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.